Cardiovascular diseases (CVDs) remain a leading cause of global mortality and morbidity. Traditional risk prediction models, while foundational, often fail to capture the multifaceted nature of risk factors or leverage the expanding pool of healthcare data. Machine learning (ML) and artificial intelligence (AI) approaches represent a paradigm shift in risk prediction, offering dynamic, scalable solutions that integrate diverse data types. This review examines advancements in AI/ML for CVD risk prediction, analyzing their strengths, limitations, and the challenges associated with their clinical integration. Recommendations for standardization, validation, and future research directions are provided to unlock the potential of these technologies in transforming precision cardiovascular medicine.
Aim Several biomarkers are currently used as diagnostic and prognostic tools in patients with cancer. Soluble urokinase plasminogen activator receptor (suPAR) is elevated in acute and chronic inflammatory procedures and several observational studies during the last 20 years have investigated its role in oncology. The purpose of this article was to review the current literature regarding suPAR’s role in clinical practice.Methods A systematic literature search of PubMed, Scopus, OpenGrey and Cochrane Library databases through September2021 was conducted using the following search terms: “supar” or “soluble urokinase plasminogen receptor” and “cancer” or “malignancy”. Original articles reporting on suPAR’s role in the diagnosis, prognosis and prediction of therapeutic outcomes in patients with confirmed or suspected cancer were included.Results Among 45 found articles, the most were observational cohort studies. The included studies were further categorized bycancer site. SuPAR level was higher in patients with cancer compared to healthy controls, but its diagnostic and prognostic accuracy differs depending on the site of cancer.Conclusion SuPAR has promising aspects in the field of oncology and public health and future research should further investigateits use in clinical practice. As it is elevated in different types of cancer, it could potentially serve as an adjunctive tool for the mass screening of patients with non-specific signs of cancer, but larger cohort studies that support these findings must be conducted.